Sales and Marketing

Pharma companies involved in the sale of heartburn therapy Zantac have won a key battle in litigation brought

US court throws out lawsuits alleging Zantac caused cancer

https://pharmaphorum.com/news/us-court-throws-out-lawsuits-alleging-zantac-caused-cancer/

Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit

Phil Taylor BioNTech, litigation, Moderna, mRNA, mRNA vaccines, patent litigation, Pfizer 0 Comment

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent, despite centring on their mRNA-based

Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit

https://pharmaphorum.com/news/pfizer-biontech-strike-back-in-moderna-covid-vaccine-lawsuit/

News/ News/ Sales and Marketing

Sanofi, Amgen acknowledge Horizon interest as J&J steps back

Phil Taylor Amgen, Horizon Therapeutics, Johnson & Johnson, M&A, Sanofi 0 Comment

Amgen and Sanofi have said they may make cash-only offers for Horizon Therapeutics, which confirmed it was in

Sanofi, Amgen acknowledge Horizon interest as J&J steps back

https://pharmaphorum.com/news/amgen-sanofi-acknowledge-horizon-interest-as-jj-steps-back/

News/ News/ Sales and Marketing

LEO Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis

Nicole Raleigh Adbry, adolescent treatment, atopic dermatitis, EC, LEO Pharma, MHRA, tralokinumab 0 Comment

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) have approved a change to

LEO Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis

https://pharmaphorum.com/news/leo-pharmas-adtralza-approved-by-mhra-ec-for-adolescent-atopic-dermatitis/

News/ News/ Sales and Marketing

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

Phil Taylor Grunenthal, Kyowa Kirin, M&A, pain, Sales and Marketing 0 Comment

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

https://pharmaphorum.com/news/grunenthal-buys-into-kyowa-kirins-mature-medicines-portfolio/

News/ News/ News/ R&D/ Sales and Marketing

J&J builds case for antidepressant Spravato with head-to-head trial

Phil Taylor depression, Janssen, Johnson & Johnson, Psychiatry, Spravato 0 Comment

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in

J&J builds case for antidepressant Spravato with head-to-head trial

https://pharmaphorum.com/news/jj-builds-case-for-antidepressant-spravato-with-head-to-head-trial/

Events/ Insights/ Reuters Pharma 2022/ Sales and Marketing/ Views and analysis

A Reuters Pharma conversation with EY: smart reviewing and payment outcomes

Nicole Raleigh AI, data, EY Consulting, health outcomes, machine learning, patient centricity, payment outcomes, pharma, Reuters Pharma, Smart Reviewer 0 Comment

Harking back to the Reuters Pharma 2022 event, held at the Nice Acropolis convention centre on France’s South

A Reuters Pharma conversation with EY: smart reviewing and payment outcomes

https://pharmaphorum.com/views-and-analysis/a-reuters-pharma-conversation-with-ey-smart-reviewing-and-payment-outcomes/

Market Access/ News/ News/ News/ Sales and Marketing

uniQure, CSL claim first okay for haemophilia B gene therapy

Phil Taylor CSL, gene therapy, Haematology, haemophilia, haemophilia B, Hemgenix, regulatory approval, uniQure 0 Comment

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for

uniQure, CSL claim first okay for haemophilia B gene therapy

https://pharmaphorum.com/news/uniqure-csl-claim-first-okay-for-a-haemophilia-b-gene-therapy/

News/ News/ News/ Oncology/ Sales and Marketing

GSK will pull Blenrep from US market after failed trial

Phil Taylor Blenrep, GlaxoSmithKline, multiple myeloma, Oncology, regulatory, Sales and Marketing 0 Comment

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported

GSK will pull Blenrep from US market after failed trial

https://pharmaphorum.com/news/gsk-will-pull-blenrep-from-us-market-after-failed-trial/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Sales and Marketing

Login